Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

David B. Pall, PhD (1914-2004).

Jeffrey S Dlott1, Dan A Waxman

  • 1Indiana Blood Center, Indianapolis, 46208, USA.

Transfusion Medicine Reviews
|December 24, 2005
PubMed
Summary
This summary is machine-generated.

David B. Pall pioneered filtration technology, most notably inventing the first leukoreduction filter for transfusion medicine. His innovations also impacted aerospace, microelectronics, and contamination control, with his legacy continuing through Pall Corporation.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation of Serotonin Release Assay Positivity With ELISA OD Value and Impact on the Management of Patients Suspected With HIT.

International journal of laboratory hematology·2026
Same author

Prevalence of Futility Protocols for Severely Bleeding Trauma Patients: A Survey from the Association for the Advancement of Blood & Biotherapies (AABB).

Journal of clinical medicine·2026
Same author

The Effect of Heterogeneous Definitions of Massive Transfusion on Using Blood Component Thresholds to Predict Futility in Severely Bleeding Trauma Patients.

Journal of clinical medicine·2025
Same author

Markers of Futile Resuscitation in Traumatic Hemorrhage: A Review of the Evidence and a Proposal for Futility Time-Outs during Massive Transfusion.

Journal of clinical medicine·2024
Same author

Traumatic Brain Injury as an Independent Predictor of Futility in the Early Resuscitation of Patients in Hemorrhagic Shock.

Journal of clinical medicine·2024
Same author

Magnesium homeostasis in deoxygenated sickle erythrocytes is modulated by endothelin-1 via Na<sup>+</sup> /Mg<sup>2+</sup> exchange.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2022
Same journal

Evaluating the Safety of Tranexamic Acid in Cancer Surgery: Clinical Evidence and Biological Rationale.

Transfusion medicine reviews·2026
Same journal

Assessment of CTLA-4, LAG-3, and TIM-3 Expression in Pediatric Patients With β-Thalassemia Major and Their Association With Alloimmunization.

Transfusion medicine reviews·2026
Same journal

A Reply to "Beyond Implementation: The Need for Validation, Equity, and Real-World Accountability in AI for Transfusion Medicine".

Transfusion medicine reviews·2026
Same journal

Beyond Implementation: The Need for Validation, Equity, and Real-World Accountability in AI for Transfusion Medicine.

Transfusion medicine reviews·2026
Same journal

Trust Over Knowledge: Rethinking Donor Iron Supplementation Strategies in Modern Blood Services-Authors' reply.

Transfusion medicine reviews·2026
Same journal

The Effect of Stress Ball and Music on Anxiety, Distress, and Pain Levels During Platelet Apheresis Donation: Randomized Controlled Trial.

Transfusion medicine reviews·2026
See all related articles

Area of Science:

  • Biomedical Engineering
  • Materials Science
  • Medical Technology

Background:

  • This article highlights the significant contributions of David B. Pall, PhD, to transfusion medicine and broader industrial filtration.
  • The information is derived from Dr. Pall's personal history, family accounts, and the company he founded, Pall Corporation.

Discussion:

  • Dr. Pall's most recognized invention in transfusion medicine is the world's first leukoreduction filter.
  • Beyond medicine, his pioneering work in filtration found critical applications in aerospace, microelectronics, and general industry.
  • His innovations also extended to advanced contamination control solutions.

Key Insights:

  • The development of the first leukoreduction filter revolutionized transfusion safety.
  • David B. Pall's filtration expertise demonstrated versatile applicability across diverse high-tech sectors.
  • Pall Corporation, founded by Dr. Pall, continues to uphold his legacy of innovation in filtration technology.

Outlook:

  • Continued advancements in filtration technology are expected, building on Dr. Pall's foundational work.
  • The principles of filtration pioneered by Dr. Pall will likely influence future developments in contamination control and advanced materials.
  • The enduring impact of his inventions underscores the importance of interdisciplinary innovation in science and industry.